Welcome to our dedicated page for FEMASYS SEC filings (Ticker: FEMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing can feel like parsing medical jargon and regulatory code at once—especially when Femasys Inc. details FDA trial phases, device patents, and funding rounds in single documents. If you’ve opened the company’s 10-K only to search for pivotal FemBloc clinical data or revenue from FemaSeed, you’re not alone.
Stock Titan’s AI turns those dense reports into plain language summaries the moment they hit EDGAR. Instantly see which section of the Femasys quarterly earnings report 10-Q filing discusses cash runway, or receive real-time alerts when a director files Femasys insider trading Form 4 transactions. Our platform covers every form:
- 10-K and 10-Q filings—find R&D spend and market-launch timelines with one-click Femasys earnings report filing analysis
- 8-K updates—get Femasys 8-K material events explained, from FDA clearances to patent grants
- DEF 14A proxy—track Femasys proxy statement executive compensation and board governance tied to clinical milestones
- Form 4—monitor Femasys Form 4 insider transactions real-time to gauge executive confidence
Need answers fast? Ask natural questions like “How is FemVue revenue trending?”—our engine replies by linking the exact paragraph in the filing. Whether you’re understanding Femasys SEC documents with AI for due diligence or comparing insider buys via Femasys executive stock transactions Form 4, every disclosure is indexed, summarized, and searchable within minutes. Complex women’s-health innovations deserve clarity; we deliver it, so you can focus on investment decisions instead of page counts.
Femasys Inc. is offering common stock in an S-1 that would leave roughly 44.0 million shares outstanding immediately after the offering (or 45.7 million if underwriters fully exercise their option). The prospectus describes a registered offering with an assumed illustrative price of $0.70 per share, a 7% underwriting discount and estimated offering expenses of about $0.8 million. The company recently secured a $10 million equity line (Any Market Purchase Agreement) and reports CE mark approvals for its FemBloc system components in 2025, strategic Spanish distribution for FemBloc, and an active pivotal U.S. trial (NCT05977751). Material dilutive instruments include convertible notes convertible at $1.18 and various options and warrants. Use of proceeds is for product development, commercialization and general corporate purposes.
Femasys Inc. reported results for the quarter ended June 30, 2025. Quarterly sales rose to $409,268 (six months $750,532), driven by increased FemaSeed and FemVue sales. The company recorded a net loss of $(4,585,922) for the quarter and $(10,482,761) for the six months, with six-month net loss per share of $(0.39). Cash and cash equivalents were $3,218,067, total assets $13,780,409, total liabilities $12,272,974, and an accumulated deficit of $137,681,018. Inventory increased to $5,232,738.
The filing highlights regulatory and commercial milestones: CE mark certification under EU MDR for the FemBloc delivery system (March 2025) and for the class III blended polymer component (June 2025), strategic distribution in Spain, enrollment of the U.S. pivotal trial, and subsequent commercial and regulatory updates including an approximate $400,000 order in Spain and Australia/New Zealand approvals announced July 1, 2025. Financing activity included at-the-market sales (~$5.5M in H1 2025) and a June 2025 underwritten offering (gross $4.51M, net proceeds $3.705M). Management states substantial doubt exists about the company’s ability to continue as a going concern and discloses Nasdaq non-compliance notices with deadlines to regain compliance.
Femasys Inc. announced its financial results for the quarter ended June 30, 2025 and provided a corporate update. The company furnished a press release as Exhibit 99.1 to this Current Report; the text states the release is being furnished, not "filed," under the Exchange Act and therefore is not subject to Section 18 liability or automatically incorporated by reference into other filings. This 8-K text does not include financial figures or operating metrics; readers must consult Exhibit 99.1 for the detailed results and corporate update. The filing identifies the company as an emerging growth company and shows its Nasdaq ticker as FEMY.
FAQ
What is the current stock price of FEMASYS (FEMY)?
What is the market cap of FEMASYS (FEMY)?
